Credit Suisse Ag Denali Therapeutics Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 1,566,246 shares of DNLI stock, worth $39.2 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,566,246

Previous 1,576,221 0.63%

Holding current value

$39.2 Million

Previous $33.8 Million 4.98%

% of portfolio

0.03%

Previous 0.03%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$15.83 - $23.35 $157,904 - $232,916	-9,975 Reduced 0.63%	1,566,246 $32.1 Million
Q4 2023 Feb 08, 2024	BUY	$16.2 - $23.18 $144,374 - $206,580	8,912 Added 0.57%	1,576,221 $33.8 Million
Q3 2023 Nov 13, 2023	SELL	$20.63 - $30.17 $118,395 - $173,145	-5,739 Reduced 0.36%	1,567,309 $32.3 Million
Q2 2023 Aug 11, 2023	BUY	$23.37 - $32.96 $457,491 - $645,224	19,576 Added 1.26%	1,573,048 $46.4 Million
Q1 2023 May 10, 2023	BUY	$21.91 - $32.67 $440,149 - $656,307	20,089 Added 1.31%	1,553,472 $35.8 Million
Q4 2022 Feb 13, 2023	SELL	$26.28 - $33.92 $2.05 Million - $2.65 Million	-78,046 Reduced 4.84%	1,533,383 $42.6 Million
Q3 2022 Nov 10, 2022	SELL	$25.97 - $38.53 $9.05 Million - $13.4 Million	-348,596 Reduced 17.79%	1,611,429 $49.5 Million
Q2 2022 Aug 12, 2022	BUY	$20.88 - $35.19 $30,296 - $51,060	1,451 Added 0.07%	1,960,025 $57.7 Million
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $147,146 - $239,847	-5,074 Reduced 0.26%	1,958,574 $63 Million
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $801,756 - $1.04 Million	-18,825 Reduced 0.95%	1,963,648 $87.6 Million
Q3 2021 Nov 12, 2021	BUY	$48.48 - $78.23 $773,983 - $1.25 Million	15,965 Added 0.81%	1,982,473 $100 Million
Q2 2021 Aug 16, 2021	BUY	$50.3 - $78.44 $428,304 - $667,916	8,515 Added 0.43%	1,966,508 $154 Million
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $29.9 Million - $45.3 Million	555,243 Added 39.58%	1,957,993 $112 Million
Q4 2020 Feb 12, 2021	BUY	$36.89 - $93.56 $48.7 Million - $124 Million	1,321,486 Added 1626.16%	1,402,750 $117 Million
Q3 2020 Nov 13, 2020	SELL	$23.13 - $38.84 $494,588 - $830,515	-21,383 Reduced 20.83%	81,264 $2.91 Million
Q2 2020 Aug 12, 2020	BUY	$16.01 - $28.82 $982,053 - $1.77 Million	61,340 Added 148.5%	102,647 $2.48 Million
Q1 2020 May 13, 2020	SELL	$14.2 - $27.98 $9,897 - $19,502	-697 Reduced 1.66%	41,307 $723,000
Q4 2019 Feb 12, 2020	SELL	$14.4 - $19.99 $84,873 - $117,821	-5,894 Reduced 12.31%	42,004 $732,000
Q3 2019 Nov 12, 2019	BUY	$15.32 - $21.92 $102,812 - $147,105	6,711 Added 16.29%	47,898 $734,000
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $84,674 - $128,796	-4,577 Reduced 10.0%	41,187 $854,000
Q1 2019 May 14, 2019	BUY	$17.99 - $24.65 $30,097 - $41,239	1,673 Added 3.79%	45,764 $1.06 Million
Q4 2018 Feb 13, 2019	BUY	$13.88 - $21.75 $252,574 - $395,784	18,197 Added 70.27%	44,091 $910,000
Q3 2018 Nov 13, 2018	BUY	$12.46 - $21.74 $173,941 - $303,490	13,960 Added 116.98%	25,894 $564,000
Q2 2018 Aug 14, 2018	BUY	$15.25 - $21.02 $181,993 - $250,852	11,934 New	11,934 $181,000

Others Institutions Holding DNLI

# of Institutions

228

Shares Held

120M

Call Options Held

60.6K

Put Options Held

48.4K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.36B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account